Leo Pharma goes hunting with the help of banks and owners

The money comes from Leo Pharma’s bankers and the ownership in the form of the Leo Foundation and Nordic Capital.

The time has come for Leo Pharma, a 115-year-old Danish pharmaceutical company, to start accelerating to ensure future growth.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom

The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.
For subscribers
Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers

Chairman praised successful turnaround in GN Hearing despite financial decline

GN Hearing is in no better place financially today than it was in 2019.

For subscribers

AJ Vaccine's loss has shrunk to USD 70 million from USD 39 million, and this is solely due to an effort to get employees to communicate better, | Photo: Aj Vaccines / Pr

Pharma & biotech

New CEO has brought change to AJ Vaccines: There was a distinct lack of communication

Ole Vahlgren has completed his first full financial year as CEO of AJ Vaccines, and it has been a start-up with a focus on strengthening communication both internally and externally.

For subscribers

Pharma & biotech

After two years of losses Leo Pharma is on track to profitability

The pharmaceutical company is on track to deliver on the big goal: to become profitable by 2023.

For subscribers

Hearing health

GN: Merger of Hearing and Audio divisions will boost innovation

The products in GN’s two divisions are becoming more and more similar, says Chairman of the Board Jukka Pertola.

For subscribers

Novo Nordisk Foundation's investment company, Novo Holdings, together with Gurnet Point Capital, has completed the acquisition of the US biotech company Paratek for USD 462 million including debt corresponding to DKK 3.2 billion. | Photo: Novo Holdings / Pr

Pharma & biotech

Novo Holdings completes acquisition of US antibiotics company for DKK 3.2bn

The acquisition of Paratek Pharmaceuticals is Novo Holdings’ largest single investment in antimicrobial resistance treatments to date.

For subscribers

The hearing group WS Audiology, the result of the 2019 merger between Widex and Sivantos, has no plans to integrate the two hearing aid platforms from each of the respective companies before the merger. | Photo: Ws Audiology / Pr

Hearing health

WS Audiology has no plans of merging product platforms

Hearing health group WS Audiology continues to see benefits in having a product platform under both Signia and Widex brands. Analysts also see benefits.

For subscribers